In late July, Clarivate announced that starting from the next Journal Citation Report (JCR) release, expected in June 2023, all journals indexed by the Emerging Science Citation Index (ESCI) and the Arts and Humanities Citation Index (AHCI) will receive an Impact Factor.
So far, the score was only available for journals in the Science Citation Index Expanded (SCIE) and the Social Sciences Citation Index (SSCI).
The news means that the following journals using the ARPHA publishing platform will receive their first Impact Factor next year:
The 2023 JCR report will reflect how many times publications in a particular journal from the Web of Science database have been cited in scholarly articles published in other journals from the same database during 2022. Then, this number will be divided by the number of ‘citable items’ published in the journal in the preceding two years (i.e. research articles, review papers and proceedings papers published in 2021 and 2020).
Note that while citations of any article type are counted in the numerator of the ratio, ‘non-citable items’, such as editorials, letters, obituaries, meeting abstracts and corrigenda, are left out of the denominator.
Can we forecast the Impact Factor?
Unfortunately, we can only guess what the first Impact Factor for any of those journals will be like.
While you can find the Scopus CiteScore for each of them displayed on the journal’s website homepages, we need to remind you that Web of Science and Scopus use their own databases and apply quite different formulae.
The Scopus CiteScore is calculated from the number of citations made over the last four completed years divided by the publications from the same years. Apart from a yearly score for the last complete year, Scopus also presents a CiteScoreTracker, whose estimate is updated on a monthly basis.
A comprehensive post, published on the independent Scholarly Kitchen blog provides further details and discussion on what the change could mean for journals in the ESCI index. The post also includes a short interview with Dr. Nandita Quaderi, Editor in Chief and Editorial Vice President, Web of Science.
The established Pharmacia demonstrates a complete makeover in its new issue after signing with scientific publisher and technology provider Pensoft and its signature open-access platform
Launched by the Bulgarian Pharmaceutical Scientific Society in 1954, the open-access, peer-reviewed Pharmacia has been available online as full text since 2007. As of 2019, the journal moves to the fast-expanding portfolio of scholarly publisher and technology provider Pensoft. The journal’s 2019 inaugural issue and the first since the realisation of the new partnership is already live on the journal’s new website.
Thanks to the Pensoft’s signature open-access scholarly publishing platform ARPHA, Pharmacia demonstrates a complete makeover, including a modern and user-friendly interface in addition to a long list of high-tech perks, meant to ensure that published articles are easy to discover, access, cite and reuse by both humans and machines all over the world.
Furthermore, all users of the journal’s system: authors, editors and reviewers alike, are to greatly benefit of ARPHA’s integrated approach to the publication process. This means that once submitted each manuscript goes through the whole cycle: from review and copy/layout editing to publication, dissemination and archiving without leaving ARPHA’s collaboration-focused online environment.
One of the interesting features now available in Pharmacia is the article-level metrics available thanks to the partnership between ARPHA and the revolutionary discovery and analytics tools Dimensions and Altmetric. By searching through millions of research articles, grant applications, clinical trials, as well as policy documents, news stories, blogs and social media posts, they allow for each article’s references and citations in both the academic and the public sphere to be monitored in real time.
Continuing its tradition, the journal welcomes original research and review articles, preliminary and short communications (notes) on a wide range of topics within the pharmaceutical and related sciences. In addition, the journal also publishes conference reports, biographies and book reviews. Articles in Pharmacia are published in English and subjected to single-blind peer review.
“We have been looking forward to our collaboration with Pensoft and ARPHA, as it is certainly going to not only help modernise Pharmacia on the outside, but also make it more appealing to our authors and readers by building on the journal’s accessibility and global outreach. I believe that this nice step forward is already clearly evident in Pharmacia‘s latest issue.”
ARPHA’s and Pensoft’s founder and CEO Prof Lyubomir Penev says:
“I’m delighted to see this particular journal joining the Pensoft’s and ARPHA’s family,” says ARPHA’s and Pensoft’s founder and CEO Prof. Lyubomir Penev. “With our strong background in scholarly publishing, technology development and open science practices, I am certain that we are able to provide the right venue for a high-quality and enterprising journal like Pharmacia.”
About the Bulgarian Pharmaceutical Scientific Society:
The Bulgarian Pharmaceutical Scientific Society was registered in 2003 with the aim to organise national and international science forums, support education and publish academic literature. Its main objectives are to organise and encourage pharmacological research and support collaboration between pharmacology professionals and related organisations on both national and global level.